Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Up to $2.66

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $2.66, but opened at $2.97. Lyell Immunopharma shares last traded at $3.04, with a volume of 522,185 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price objective on Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, February 29th.

Lyell Immunopharma Stock Performance

The firm has a market cap of $764.83 million, a price-to-earnings ratio of -3.24 and a beta of -0.56. The business’s 50 day moving average price is $2.23 and its 200 day moving average price is $1.99.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $4.96 million. Sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its stake in shares of Lyell Immunopharma by 16.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 627,695 shares of the company’s stock worth $1,218,000 after purchasing an additional 90,078 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Lyell Immunopharma during the fourth quarter valued at approximately $29,000. Virtus ETF Advisers LLC raised its stake in Lyell Immunopharma by 59.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 45,832 shares of the company’s stock valued at $89,000 after purchasing an additional 17,171 shares during the last quarter. Barclays PLC lifted its holdings in Lyell Immunopharma by 7.3% in the 4th quarter. Barclays PLC now owns 263,070 shares of the company’s stock valued at $510,000 after purchasing an additional 17,827 shares in the last quarter. Finally, Prelude Capital Management LLC acquired a new stake in Lyell Immunopharma during the 4th quarter worth $34,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.